Cypress Bioscience, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cypress Bioscience, Inc.
Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.
Inspired by the discovery of the phytochemical corynoline being a potential MYC synthetic lethality agent, Anticancer Bioscience has designed and identified preclinical candidates that could lead to first-in-class innovative drugs.
The three companies have joined forces to launch Aurobac Therapeutics, combining their respective strengths to develop a precision approach to treating infections.
Among the highlights of MedTech Europe’s annual MedTech Forum are the “unfiltered” views offered by company CEOs on the entire range of issues that influence decision-making or will have an impact on business operations in the near term.
- Medical Devices
In Vitro Diagnostics
- Therapeutic Drug Monitoring
- Other Names / Subsidiaries
- Cellatope Corporation
- Proprius Pharmaceuticals, Inc., Ramius LLC
- Royalty Pharma